Dr. Mark Dudley is a Senior Vice President at Adaptimmune Therapeutics, a leader in genetically modified T cell therapies for solid cancers, where he is responsible for Product Development. Dr. Dudley is a pioneer in the field of cell and gene therapies, and has implemented innovative process design, product analysis, and lifecycle management for cellular therapies from exploratory clinical trials to commercial products. His work has resulted in more than 100 peer-reviewed publications including seminal studies demonstrating that a patient’s own T-cells can mediate complete responses in advanced refractory cancer. Dr. Dudley earned a Ph.D. in Biological Sciences at Stanford University, and post-doctoral fellowships at The University of Pennsylvania and at the Jackson Laboratory in Bar Harbor, ME.